Abstract
Quercetin is an abundant micronutrient in our daily diet. Several beneficial health effects are associated with the dietary uptake of this bioflavonoid, including alleviating effects on chronic inflammation and atherosclerosis. A variety of in vitro data indicate a possible use of quercetin for cancer treatment purposes through its interaction with multiple cancer-related pathways. Among these, recent data reveal that quercetin can inhibit mTOR activity in cancer cells. Inhibition of the mTOR signaling pathway by quercetin has directly been described and can further be deduced from its interference with PI3K-dependent Akt stimulation, AMP-dependent protein kinase activation and hamartin upregulation. The ability of quercetin to interfere with both mTOR activity and activation of the PI3K/Akt signaling pathway gives quercetin the advantage to function as a dual-specific mTOR/PI3K inhibitor. The mTOR complex, often hyperactivated in cancer, is a crucial regulator of homeostasis controlling essential pathways leading to cell growth, protein biosynthesis and autophagy. The ability of quercetin to inhibit mTOR activity by multiple pathways makes this otherwise safe bioflavonoid an interesting tool for the treatment of cancers and other diseases associated with mTOR deregulation.
Keywords: Quercetin, autophagy, mTOR, AMPK, Akt, proteasome, anti-oxidant, cancer.
Anti-Cancer Agents in Medicinal Chemistry
Title:Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Volume: 13 Issue: 7
Author(s): Ansgar Bruning
Affiliation:
Keywords: Quercetin, autophagy, mTOR, AMPK, Akt, proteasome, anti-oxidant, cancer.
Abstract: Quercetin is an abundant micronutrient in our daily diet. Several beneficial health effects are associated with the dietary uptake of this bioflavonoid, including alleviating effects on chronic inflammation and atherosclerosis. A variety of in vitro data indicate a possible use of quercetin for cancer treatment purposes through its interaction with multiple cancer-related pathways. Among these, recent data reveal that quercetin can inhibit mTOR activity in cancer cells. Inhibition of the mTOR signaling pathway by quercetin has directly been described and can further be deduced from its interference with PI3K-dependent Akt stimulation, AMP-dependent protein kinase activation and hamartin upregulation. The ability of quercetin to interfere with both mTOR activity and activation of the PI3K/Akt signaling pathway gives quercetin the advantage to function as a dual-specific mTOR/PI3K inhibitor. The mTOR complex, often hyperactivated in cancer, is a crucial regulator of homeostasis controlling essential pathways leading to cell growth, protein biosynthesis and autophagy. The ability of quercetin to inhibit mTOR activity by multiple pathways makes this otherwise safe bioflavonoid an interesting tool for the treatment of cancers and other diseases associated with mTOR deregulation.
Export Options
About this article
Cite this article as:
Bruning Ansgar, Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (7) . https://dx.doi.org/10.2174/18715206113139990114
DOI https://dx.doi.org/10.2174/18715206113139990114 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intracranial MR Dynamics in Clinically Diagnosed Alzheimers Disease: The Emerging Concept of “Pulse Wave Encephalopathy”
Current Alzheimer Research Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections
Current Pharmaceutical Design Thrombophilia in Pregnancy: Maternal and Fetal Implications
Current Women`s Health Reviews Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism Applied Proteomics in Companion Animal Medicine
Current Proteomics Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot Topic (1): Update on Inflammatory Processes Governing Atherosclerotic Plaque Vulnerability and Reperfusion Injury (Guest Editors: Fabrizio Montecucco and Francois Mach)]
Current Pharmaceutical Biotechnology Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety The Impact of Methodology and Confounding Variables on the Association Between Major Depression and Coronary Heart Disease: Review and Recommendations
Current Psychiatry Reviews Evaluation of Ischemic Heart Disease Factors in Hemophilia Patients in Khorramabad
Cardiovascular & Hematological Disorders-Drug Targets Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science A Review of Recent Patents (2016-2019) on Plant Food Supplements with Potential Application in the Treatment of Neurodegenerative and Metabolic Disorders
Recent Patents on Food, Nutrition & Agriculture Early Pathogenesis of Atherosclerosis: The Childhood Obesity
Current Pharmaceutical Design Commentary : Hypothesis Focused Ultrasound and NXY-059 in Experimental Cerebral Ischemia: A New Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets GPU-Based Acceleration of ECG Characterization Using High-Order Hermite Polynomials
Current Bioinformatics Treatment of Hypertensive Left Ventricular Hypertrophy
Current Pharmaceutical Design Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk
Current Pharmaceutical Design